# SRD5A2

## Overview
The SRD5A2 gene encodes the enzyme steroid 5α-reductase type 2, a critical component in the biochemical conversion of testosterone to dihydrotestosterone (DHT), a more potent androgen. This enzyme is categorized as a transmembrane protein, characterized by its seven-transmembrane domain structure, which facilitates its function within the endoplasmic reticulum membrane (Seo2023The; Xiao2020Structure). The SRD5A2 enzyme plays a pivotal role in male sexual differentiation and development, particularly during embryogenesis, by catalyzing the reduction of testosterone, thereby influencing the formation of male external genitalia and the prostate (Thigpen1992Molecular; Seo2023The). Mutations in the SRD5A2 gene can lead to steroid 5α-reductase type 2 deficiency, resulting in a spectrum of clinical manifestations related to undervirilization (Batista2022The). Additionally, the enzyme's interaction with pharmacological agents like finasteride underscores its significance in therapeutic contexts, particularly in conditions such as benign prostatic hyperplasia and androgenic alopecia (Xiao2020Structure).

## Structure
The SRD5A2 gene encodes the enzyme steroid 5α-reductase 2, which is involved in the conversion of testosterone to dihydrotestosterone (DHT). The protein is characterized by a seven-transmembrane (7-TM) domain topology, which is distinct from the typical arrangement seen in G protein-coupled receptors (Xiao2020Structure). This 7-TM structure is connected by six loops, forming a large substrate-binding cavity inside the transmembrane domain (Seo2023The). The enzyme's active site includes key residues such as E57 and Y91, which are crucial for substrate binding and catalytic activity, facilitating the hydride transfer from NADPH to testosterone (Han2020Crystal; Xiao2020Structure).

The SRD5A2 protein is embedded in the endoplasmic reticulum membrane and is primarily composed of alpha-helices (Seo2023The). The structure includes specific domains for cofactor and substrate binding, with tunnel-like pockets for NADPH and steroid substrates (Xiao2020Structure). Post-translational modifications such as glycosylation may occur, although specific details are not provided in the context. Variants in the SRD5A2 gene can lead to different isoforms, potentially affecting the enzyme's function (Seo2023The). The protein's structure and function are critical for understanding its role in steroid metabolism and its interaction with inhibitors like finasteride (Xiao2020Structure).

## Function
The SRD5A2 gene encodes the enzyme steroid 5α-reductase type 2, which is essential for the conversion of testosterone into dihydrotestosterone (DHT), a more potent androgen. This conversion is crucial for the development of male external genitalia and the prostate during embryonic development (Thigpen1992Molecular; Seo2023The). The enzyme operates by catalyzing the reduction of 3-oxo-Δ4 steroids, such as testosterone, into their respective 5α-dihydro forms, using NADPH as a cofactor (Han2020Crystal; Seo2023The). 

In healthy human cells, SRD5A2 is predominantly active in reproductive tissues, including the prostate, liver, and skin, where it plays a significant role in male sexual differentiation and development (Katharopoulos2019In; Thigpen1993Tissue). The enzyme's activity is facilitated by a conserved mechanism involving the binding of NADPH and the substrate within a semi-closed pocket formed by transmembrane segments (Han2020Crystal). 

DHT, the product of this enzymatic reaction, is a potent androgen that binds to androgen receptors, regulating gene expression and contributing to the development of male secondary sexual characteristics (Katharopoulos2019In). The enzyme's function is vital for maintaining normal male sexual development, and defects in the SRD5A2 gene can lead to conditions such as 5α-reductase type 2 deficiency, characterized by genital ambiguity (Seo2023The).

## Clinical Significance
Mutations in the SRD5A2 gene lead to steroid 5α-reductase 2 deficiency, an autosomal recessive disorder affecting individuals with a 46,XY karyotype. This condition results in a range of undervirilization of external genitalia, from almost typically female to predominantly male with minimal undervirilization, such as isolated micropenis (Thigpen1992Molecular; Batista2022The). The deficiency is characterized by an increased testosterone to dihydrotestosterone (DHT) ratio due to impaired conversion, affecting the development of male external genitalia, prostate, and urethra (Seo2023The). 

The clinical presentation of this deficiency is heterogeneous, with some individuals being virilized enough to be raised as males, while others may present with ambiguous genitalia at birth and significant virilization at puberty (Vilchis2000Identification; Vilchis2008Novel). The condition can lead to male pseudohermaphroditism, hypospadias, microphallus, and cryptorchid testes (Vilchis2000Identification). 

Mutations in the SRD5A2 gene have also been linked to other conditions such as benign prostatic hyperplasia, male pattern baldness, acne, female hirsutism, and possibly prostate cancer (Ramos2020Mutational). The gene's polymorphisms, such as p.V89L and p.A49T, have been studied in relation to prostate cancer risk, with varying associations across different populations (Batista2020&lt; p&gt; Integrative).

## Interactions
The human steroid 5α-reductase 2 (SRD5A2) enzyme is involved in the conversion of testosterone to dihydrotestosterone (DHT), a process that requires interaction with the cofactor NADPH. The enzyme's structure includes a binding cavity for NADPH and steroid substrates, with cytosolic loops playing a role in enclosing this pocket (Xiao2020Structure). Specific residues, such as E57 and R114, facilitate interactions with NADPH and the anti-androgen drug finasteride, forming an intermediate adduct that inhibits the enzyme's activity (Xiao2020Structure). 

Mutations in SRD5A2 can affect these interactions, as seen with the p.R227Q mutation, which alters the interaction between SRD5A2 and NADPH by increasing the distance between the ribose ring of NADPH and the protein, potentially disrupting the enzyme's function (Seo2023The). The enzyme's interaction with finasteride, a drug used to treat conditions like benign prostatic hyperplasia, involves the formation of a stable NADP-DHF adduct, which irreversibly inhibits SRD5A2 by preventing the exchange of NADPH/NADP+ (Xiao2020Structure). These interactions highlight the enzyme's role in androgen metabolism and its potential as a therapeutic target.


## References


[1. (Vilchis2000Identification) Vilchis, Méndez, Canto, Lieberman, and Chávez. Identification of missense mutations in the srd5a2 gene from patients with steroid 5α‐reductase 2 deficiency. Clinical Endocrinology, 52(3):383–387, March 2000. URL: http://dx.doi.org/10.1046/j.1365-2265.2000.00941.x, doi:10.1046/j.1365-2265.2000.00941.x. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1046/j.1365-2265.2000.00941.x)

[2. (Katharopoulos2019In) Efstathios Katharopoulos, Kay Sauter, Amit V. Pandey, and Christa E. Flück. In silico and functional studies reveal novel loss-of-function variants of srd5a2, but no variants explaining excess 5α-reductase activity. The Journal of Steroid Biochemistry and Molecular Biology, 190:263–272, June 2019. URL: http://dx.doi.org/10.1016/j.jsbmb.2019.01.017, doi:10.1016/j.jsbmb.2019.01.017. This article has 5 citations.](https://doi.org/10.1016/j.jsbmb.2019.01.017)

[3. (Xiao2020Structure) Qingpin Xiao, Lei Wang, Shreyas Supekar, Tao Shen, Heng Liu, Fei Ye, Junzhou Huang, Hao Fan, Zhiyi Wei, and Cheng Zhang. Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride. Nature Communications, October 2020. URL: http://dx.doi.org/10.1038/s41467-020-19249-z, doi:10.1038/s41467-020-19249-z. This article has 55 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-19249-z)

[4. (Ramos2020Mutational) L. Ramos, F. Vilchis, B. Chávez, and L. Mares. Mutational analysis of srd5a2: from gene to functional kinetics in individuals with steroid 5α-reductase 2 deficiency. The Journal of Steroid Biochemistry and Molecular Biology, 200:105691, June 2020. URL: http://dx.doi.org/10.1016/j.jsbmb.2020.105691, doi:10.1016/j.jsbmb.2020.105691. This article has 9 citations.](https://doi.org/10.1016/j.jsbmb.2020.105691)

[5. (Vilchis2008Novel) Felipe Vilchis, Evangelina Valdez, Luis Ramos, Rocio García, Rita Gómez, and Bertha Chávez. Novel compound heterozygous mutations in the srd5a2 gene from 46,xy infants with ambiguous external genitalia. Journal of Human Genetics, 53(5):401–406, March 2008. URL: http://dx.doi.org/10.1007/s10038-008-0274-2, doi:10.1007/s10038-008-0274-2. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10038-008-0274-2)

[6. (Thigpen1992Molecular) A E Thigpen, D L Davis, A Milatovich, B B Mendonca, J Imperato-McGinley, J E Griffin, U Francke, J D Wilson, and D W Russell. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. Journal of Clinical Investigation, 90(3):799–809, September 1992. URL: http://dx.doi.org/10.1172/jci115954, doi:10.1172/jci115954. This article has 304 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci115954)

[7. (Thigpen1993Tissue) A E Thigpen, R I Silver, J M Guileyardo, M L Casey, J D McConnell, and D W Russell. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. Journal of Clinical Investigation, 92(2):903–910, August 1993. URL: http://dx.doi.org/10.1172/jci116665, doi:10.1172/jci116665. This article has 547 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci116665)

8. (Han2020Crystal) Crystal structure of steroid reductase SRD5A reveals conserved steroid reduction mechanism. This article has 0 citations.

[9. (Seo2023The) Jieun Seo, Saeam Shin, Sang-woon Kim, Su Jin Kim, Myeongseob Lee, Kyungchul Song, Junghwan Suh, Seung-Tae Lee, Yong Seung Lee, Hyun Wook Chae, Ho-Seong Kim, Jong Rak Choi, Sangwon Han, and Ahreum Kwon. The genotype-phenotype correlation in human 5α-reductase type 2 deficiency: classified and analyzed from a srd5a2 structural perspective. International Journal of Molecular Sciences, 24(4):3297, February 2023. URL: http://dx.doi.org/10.3390/ijms24043297, doi:10.3390/ijms24043297. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24043297)

[10. (Batista2022The) Rafael L. Batista and Berenice B. Mendonca. The molecular basis of 5α-reductase type 2 deficiency. Sexual Development, 16(2–3):171–183, 2022. URL: http://dx.doi.org/10.1159/000525119, doi:10.1159/000525119. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000525119)